share_log

JMP Securities Reiterates Market Outperform on ProQR Therapeutics, Maintains $6 Price Target

Benzinga ·  Mar 30, 2023 09:16

JMP Securities analyst Jonathan Wolleben reiterates ProQR Therapeutics (NASDAQ:PRQR) with a Market Outperform and maintains $6 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment